Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade F 66.44 -4.80% -3.35
BPMC closed down 4.8 percent on Friday, June 22, 2018, on 1.59 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BPMC trend table...

Date Alert Name Type % Chg
Jun 22 Multiple of Ten Bearish Other 0.00%
Jun 22 Wide Bands Range Expansion 0.00%
Jun 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.80%
Jun 21 Multiple of Ten Bearish Other -4.80%
Jun 21 Outside Day Range Expansion -4.80%
Jun 21 Wide Bands Range Expansion -4.80%
Jun 21 Up 3 Days in a Row Strength -4.80%
Jun 20 Narrow Range Bar Range Contraction -4.55%
Jun 20 NR7 Range Contraction -4.55%
Jun 20 Multiple of Ten Bearish Other -4.55%

Older signals for BPMC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 109.0
52 Week Low 41.41
Average Volume 574,362
200-Day Moving Average 77.4173
50-Day Moving Average 78.7924
20-Day Moving Average 73.892
10-Day Moving Average 70.368
Average True Range 4.0743
ADX 26.23
+DI 14.67
-DI 28.94
Chandelier Exit (Long, 3 ATRs ) 73.1871
Chandelier Exit (Short, 3 ATRs ) 76.8329
Upper Bollinger Band 85.8995
Lower Bollinger Band 61.8845
Percent B (%b) 0.19
BandWidth 32.500135
MACD Line -3.4895
MACD Signal Line -3.1955
MACD Histogram -0.294
Fundamentals Value
Market Cap 2.6 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -21.29
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 74.30
Resistance 3 (R3) 75.03 73.13 72.99
Resistance 2 (R2) 73.13 71.13 72.77 72.55
Resistance 1 (R1) 69.79 69.90 68.84 69.06 72.12
Pivot Point 67.89 67.89 67.42 67.53 67.89
Support 1 (S1) 64.55 65.89 63.60 63.82 60.76
Support 2 (S2) 62.65 64.66 62.29 60.33
Support 3 (S3) 59.31 62.65 59.89
Support 4 (S4) 58.58